Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged patent · clear
As we prepare to publish our first Federal Circuit IIntelligence Report , we plan to dive deep into the Federal Circuit patent cases, their origins, filing activity and its process. In Patexia Insight 103 , we examined the current trends of patent…
Assigning a dollar amount to the entire patent prosecution market in the US has been something that kept our research team at Patexia quite busy for a while. Back in March, we reported that more than 3500 law firms had worked with over 110,000 companies to…
The disclosure requirements that will meet the written description requirement of s. 112(1) had a fairly mundane priority policing role prior to the expansion of the importance of the requirement in the biotech cases leading up to the en banc Ariad…
In early March we released our 2nd Annual Patent Prosecution Intelligence Report , where we evaluated more than 3,500 patent firms over the last five years (Jan 1, 2015 through December 31, 2019). We looked at many metrics such as number of office actions,…
In Galderma Labs. v. Teva Pharm. USA, Inc. , Appeal Nos. 2019-2396 and 2020-1213 (Fed. Cir,. January 29, 2020), a Fed. Cir. panel of Judges Moore, O’Malley and Stoll reversed a district court finding that three Galderma patents (US Pat. Nos.…
Federal Gov’t & Federal Contractors in the Court of Federal Claims – A Legal Relationship? Federal government contractors are protected from patent infringement suits when infringing activities are performed pursuant to a contract with the…
The number of U.S. issued patents from 2014 to 2018 grew by 3.6%. In 2014, the U.S. patent office granted a total of 326,038 patents. This number grew to 337,699 in 2018. However, not all companies enjoyed the same rate of growth. During this five-year…
A bill was recently proposed to “reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.” The bill would amend the patent statutes (s. 253 or title 35) for add the…
Last year, in a lengthy split decision, a Fed. Cir. panel affirmed the district court’s ruling that four “add-on” patents that Acorda owned were invalid as obviousness in view of a number of prior art references (Acorda Ther., Inc. v.…
A few weeks ago, we published the top five fastest growing patent firms . We also talked about the challenges the sector is facing and some of the concerns of law firms with shrinking profits in recent years ( Patexia Insight 54 ) . This week, we are…
Pre-AIA, 35 USC 102(b) stated that a person is entitled to a patent unless “the invention was patented or described in a printed publication… or in public use or on sale in the country, more than one year prior to the date of the application…
UCB v. Accord, Appeal no. 2016-2610 et al. (Fed. Cir., May 23, 2018) may be headed to the Supreme Court, which prompted me to take another look at this opinion. This was a decision in Hatch-Waxman litigation, in which a split Fed. Cir. panel affirmed the…
